328 related articles for article (PubMed ID: 25183770)
1. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
2. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
Homesley HD; Filiaci V; Gibbons SK; Long HJ; Cella D; Spirtos NM; Morris RT; DeGeest K; Lee R; Montag A
Gynecol Oncol; 2009 Mar; 112(3):543-52. PubMed ID: 19108877
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
[TBL] [Abstract][Full Text] [Related]
9. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer.
Shimada M; Kigawa J; Terakawa N; Yoshizaki A; Shoji T; Suzuki M; Hatae M; Tsuda H; Ohwada M; Sugiyama T
Int J Gynecol Cancer; 2007; 17(1):210-4. PubMed ID: 17291255
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
[TBL] [Abstract][Full Text] [Related]
15. [A feasibility study of doxorubicin/cisplatin (AP) for postoperative chemotherapy in patients with advanced endometrial cancer].
Nishio S; Katsumata N; Tanabe H; Matsumoto K; Yonemori K; Kouno T; Shimizu C; Ando M; Fujiwara Y
Gan To Kagaku Ryoho; 2006 Nov; 33(11):1589-93. PubMed ID: 17108724
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]